financetom
Business
financetom
/
Business
/
Altria tops quarterly profit estimates, flags $873 million NJOY impairment
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Altria tops quarterly profit estimates, flags $873 million NJOY impairment
May 25, 2025 8:44 PM

(Reuters) -Tobacco company Altria ( MO ) on Tuesday beat first-quarter profit estimates but flagged an $873 million impairment at its e-cigarette business, where shipments dropped 70% amid a patent dispute.

Rising demand for its smoking alternatives, such as on! nicotine pouches and NJOY vapes, helped the company counter the impact from lost cigarette sales as smokers shift away from traditional tobacco products.

However, its efforts to transition revenues away from tobacco have been fraught, with the latest setback being a block on the imports of its NJOY ACE vapes as part of a patent dispute with e-cigarette rival Juul Labs.

Altria ( MO ), which also makes Marlboro cigarettes, said it booked the hefty non-cash impairment on its e-cigarette division as a result and that shipments of the device had dropped after it stopped importing NJOY ACE on March 24.

The company said its full-year forecast assumes that NJOY will not return to the U.S. market this year.

The impairment dragged reported diluted earnings per share down almost 48% for the first quarter.

However, the company's adjusted quarterly profit came in at $1.23 per share, beating analysts' average estimate of $1.19 per share, according to data compiled by LSEG.

Altria ( MO ) expects a 2% to 5% increase in its adjusted earnings per share for the full year, representing a range of $5.30 to $5.45 per share, compared with the rebased figures for 2024.

Net revenue for the quarter ended March 31 fell 5.7% to $5.26 billion, topping estimates of $4.60 billion.

Quarterly shipment volume for cigarettes in the smokeable products segment fell 13.7%, compared with a 10% decline a year ago.

The shipment volume for on! nicotine pouches rose 18% for the first quarter.

Shares of the company were down about 2% in premarket trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pulsar Helium Details Samples From Topax Project
Pulsar Helium Details Samples From Topax Project
Mar 14, 2024
09:51 AM EDT, 03/14/2024 (MT Newswires) -- Pulsar Helium Inc. ( PSRHF ) said Thursday that it has received the analytical laboratory results for gas samples from the Jetstream No. 1 appraisal well at the Topaz helium project in Minnesota. The company said helium contents of up to 13.8% were measured, specifically from a sample obtained at 1,801 feet in-hole...
Mission Produce Insider Sold Shares Worth $3,264,598, According to a Recent SEC Filing
Mission Produce Insider Sold Shares Worth $3,264,598, According to a Recent SEC Filing
Mar 14, 2024
09:53 AM EDT, 03/14/2024 (MT Newswires) -- Luis A Gonzalez, 10% Owner, Director, around March 12, 2024, sold 275,143 shares in Mission Produce ( AVO ) for $3,264,598. Following the Form 4 filing with the SEC, Gonzalez has control over a total of 9,109,786 shares of the company, with 26,696 shares held directly and 9,083,090 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1802974/000182588524000002/xslF345X03/wk-form4_1710370022.xml...
Nine Energy Service Insider Sold Shares Worth $470,248, According to a Recent SEC Filing
Nine Energy Service Insider Sold Shares Worth $470,248, According to a Recent SEC Filing
Mar 14, 2024
09:47 AM EDT, 03/14/2024 (MT Newswires) -- Ann G Fox, President, CEO and Director, on March 12, 2024, sold 216,704 shares in Nine Energy Service ( NINE ) for $470,248. Following the Form 4 filing with the SEC, Fox has control over a total of 508,783 shares of the company, with 508,783 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1532286/000095017024031014/xslF345X03/ownership.xml Price: 2.08,...
Charles River Laboratories International, Navega Therapeutics Partner for Production of AAV-Based Gene Therapy
Charles River Laboratories International, Navega Therapeutics Partner for Production of AAV-Based Gene Therapy
Mar 14, 2024
09:47 AM EDT, 03/14/2024 (MT Newswires) -- Charles River Laboratories International ( CRL ) and Navega Therapeutics have entered into a partnership for the production of the NT-Z001 adeno-associated virus-based gene therapy for phase 1 clinical trials, the companies said Thursday. The production program agreement will give Navega access to Charles River's gene therapy contract development and manufacturing capabilities to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved